Cynthia R. Cherry

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

Chipman Stroud, Aparna Hegde, Cynthia R. Cherry et al. · Journal of Oncology Pharmacy Practice · 2017 · 316 citations

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Abdul Rafeh Naqash, Biagio Ricciuti, Dwight H. Owen et al. · Cancer Immunology Immunotherapy · 2020 · 93 citations · Full text

Cancer Epidemiology, Pooled Exploratory Analysis, Medicine +8

Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting

Melissa Moey, Anna Tomdio, Justin McCallen et al. · JACC CardioOncology · 2020 · 45 citations · Full text

Antibiotic use and overall survival in lung cancer patients receiving nivolumab.

Tien Phuc, Aparna Hegde, Cynthia R. Cherry et al. · Journal of Clinical Oncology · 2018 · 22 citations

Immunology, Pathology, Antimicrobial Chemotherapy +20

Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer

Kartik Sehgal, Anushi Bulumulle, Heather Brody et al. · Clinical Lung Cancer · 2020 · 20 citations · Full text

Survival Outcomes, Medicine, Immune Checkpoint Inhibitor +7